Imperial College London
Alternate

ProfessorPaoloVineis

Faculty of Medicine, School of Public Health

Chair in Environmental Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3372p.vineis Website

 
 
//

Location

 

511Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Boccardi:2017:10.1016/j.neurobiolaging.2017.01.021,
author = {Boccardi, M and Gallo, V and Yasui, Y and Vineis, P and Padovani, A and Mosimann, U and Giannakopoulos, P and Gold, G and Dubois, B and Jack, CR and Winblad, B and Frisoni, GB and Albanese, E},
doi = {10.1016/j.neurobiolaging.2017.01.021},
journal = {NEUROBIOLOGY OF AGING},
pages = {141--152},
title = {The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology},
url = {http://dx.doi.org/10.1016/j.neurobiolaging.2017.01.021},
volume = {52},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs. screening preclinical individuals), and the target population (mild cognitive impairment patients referring to memory clinics vs. general population) lead to important differences, influencing both the design of validation studies and the use of selected biomarkers. This framework is applied within a wider initiative to assess the current available evidence on the clinical validity of biomarkers for AD, for the final aim to identify gaps and research priorities, and to inform coordinated research efforts boosting AD biomarkers research.
AU  - Boccardi,M
AU  - Gallo,V
AU  - Yasui,Y
AU  - Vineis,P
AU  - Padovani,A
AU  - Mosimann,U
AU  - Giannakopoulos,P
AU  - Gold,G
AU  - Dubois,B
AU  - Jack,CR
AU  - Winblad,B
AU  - Frisoni,GB
AU  - Albanese,E
DO  - 10.1016/j.neurobiolaging.2017.01.021
EP  - 152
PY  - 2017///
SN  - 0197-4580
SP  - 141
TI  - The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology
T2  - NEUROBIOLOGY OF AGING
UR  - http://dx.doi.org/10.1016/j.neurobiolaging.2017.01.021
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000397169000016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/47894
VL  - 52
ER  -
Download